Weill Cornell Investigator Targeting Traumatic Eye Injury Secures $1.27m from DoD

Thanks to a $1.27 million grant from the United States Department of Defense (DoD), Dr. Katherine Hajjar, a medical professor and clinical investigator with Weill Cornell Medicine can focus investigation now on treatments for proliferative vitreoretinopathy (PVR), a rare but devastating eye condition largely affecting military personnel who suffer traumatic eye injuries during combat. This three-year grant supports investigation into the safety and effectiveness of two novel investigational antibodies. The expert in pediatric hematology-oncology takes on an important mission to help patients that have served their country via the armed forces. Dr. Hajjar ultimately hopes to find a willing pharmaceutical partner to conduct clinical trials should this next research prove successful.

TrialSite provides a brief overview of this important research.

What are the Incidence levels of PVR?

About 200,000 people worldwide each year sustain a penetrating wound to the eye, the main risk factor for PVR. It can also occur in some who undergo complex eye surgeries or experience a detached retina. The condition’s prevalence has risen among military personnel with the increasing use of exp...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee